Knight Therapeutics (TSE:GUD) reported record results for the first six months of 2026 and raised its full-year outlook, citing growth in its promoted products, contributions from recent launches and favorable foreign-exchange effects. For the first half of 2026, the company reported revenue of CAD

Knight Therapeutics Inc (KHTRF) posts a 34% revenue surge to $144 million in Q2 2026, driven by robust product launches and a raised full-year outlook.

Knight Therapeutics (GUD.TO) first quarter net earnings and adjusted revenue both jumped, beating fo

As the Canadian market navigates a complex landscape marked by energy supply uncertainties and mixed economic signals, investors are keeping a close eye on growth companies that could potentially lead the way in a shifting environment. In this context, stocks with strong insider ownership often attract attention, as they can indicate confidence from those closest to the company's operations and strategic direction.

As the Canadian market navigates a complex landscape marked by uncertainty around energy supply disruptions and economic surveys, investors are keenly observing how these factors might influence stock valuations. In such an environment, identifying stocks that may be trading below their estimated value can offer potential opportunities for those looking to balance growth with value in their portfolios.

As the Canadian market navigates a period of uncertainty with inflation expectations and interest rates in focus, investors are keenly watching for signals from the Federal Reserve on future monetary policy adjustments. In this environment, identifying stocks that are estimated to be below their intrinsic value can offer potential opportunities for investors seeking stability and growth amidst fluctuating economic conditions.

Knight Therapeutics (GUD.TO) reported solid fourth-quarter results, as the Paladin/Sumitomo transact

Knight Therapeutics (GUD.TO) was at last look up more than 1% Monday after saying it received accept